Glaukos
Founded Year
1998Stage
PIPE | IPOTotal Raised
$124MMarket Cap
2.35BStock Price
48.33Revenue
$0000About Glaukos
Glaukos (NYSE: GKOS) is an ophthalmic medical technology company focused on the development and commercialization of products and procedures to transform the treatment of glaucoma, one of the leading causes of blindness. Glaukos developed Micro-Invasive Glaucoma Surgery, or MIGS, in order to improve the traditional glaucoma treatment and management paradigm.
Missing: Glaukos's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Glaukos's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Glaukos
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Glaukos is included in 2 Expert Collections, including Diabetes.
Diabetes
1,900 items
Medical Devices
295 items
Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA
Glaukos Patents
Glaukos has filed 108 patents.
The 3 most popular patent topics include:
- Diseases of the eye and adnexa
- Ophthalmology
- Eye surgery
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/9/2019 | 12/13/2022 | Diseases of the eye and adnexa, Eye surgery, Ophthalmology, Glaucoma, Visual system | Grant |
Application Date | 5/9/2019 |
|---|---|
Grant Date | 12/13/2022 |
Title | |
Related Topics | Diseases of the eye and adnexa, Eye surgery, Ophthalmology, Glaucoma, Visual system |
Status | Grant |
Latest Glaukos News
Jan 19, 2023
Source: Hovanesian JA. What have you learned, Dorothy? Insights from 20+ years of premium implants. Disclosures: Hovanesian reports financial disclosures with 1-800-DOCTORS, Abbott Medical Optics, AcuFocus, Aerie, Alcon, Alicia Surgery Center, Allegro, Allergan, BlephEx, Cloudbreak Therapeutics, Cord LLC, Eyedetec, Glaukos, Guardion Health Sciences, Harvard Eye Associates, Harvard Hearing, Ingenoeye, IOP/Katena, Ivantis, Kala, MDbackline, Novartis, Ocular Therapeutix, Omeros, ReVision Optics, RxSight, Sarentis, Sensimed, Shire, Sight Sciences, TearLab, Tear Film Innovations, TLC Laser Eye Centers, Valeant and Veracity. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
Glaukos Frequently Asked Questions (FAQ)
When was Glaukos founded?
Glaukos was founded in 1998.
Where is Glaukos's headquarters?
Glaukos's headquarters is located at 229 Avenida Fabricante, San Clemente.
What is Glaukos's latest funding round?
Glaukos's latest funding round is PIPE.
How much did Glaukos raise?
Glaukos raised a total of $124M.
Who are the investors of Glaukos?
Investors of Glaukos include Novo Ventures, Versant Ventures, InterWest Partners, Frazier Healthcare Partners, OrbiMed Advisors and 7 more.
Who are Glaukos's competitors?
Competitors of Glaukos include iSTAR Medical, Implandata Ophthalmic Products, Ambrx, CytImmune Sciences, VentiRx Pharmaceuticals and 13 more.
Compare Glaukos to Competitors
Led by a team with vast experience in pharmaceuticals, ophthalmology and start-ups, Chakshu Research is committed to develop pharmaceutical treatments for degenerative ocular diseases. The company are developing a self-administered eyedrop to reduce and repair oxidative damage which has been implicated in blinding degenerative diseases. While the company's drug platform is being tested on the company's lead indication, cataract; the company are also in clinical trials for glaucoma and asteroid hyalosis.
Ausio Pharmaceuticals is a company focused on the clinical development of S-Equol for major medical needs.
Amulet Pharmaceuticals is a development stage medical device and therapeudics company where patented NORTECH „ technology aims to provide predictable and targeted time release of Nitric Oxide in the body.
Cervelo Pharmaceuticals is a semi-virtual clinical development company founded in 2006. The Company is focused on the in-licensing and development of mid stage neurology small molecule drug candidates. It currently has exclusive worldwide rights for all indications to a small molecule, first in class, drug candidate, which has demonstrated a safe and potentially effective capability against neuropathic and inflammatory pain, as well as inflammation.
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.
TenX is a biopharmaceutical company focused on late stage development and launch of novel cancer products.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.